ClinicalTrials.gg
CompletedNCT03235219Updated Apr 27, 2025

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

A Phase 1 interventional study of JNJ-64565111 and Placebo in Diabetes Mellitus, Type 2, sponsored by Janssen Research & Development, LLC. Completed at 2 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus, Type 2 · Johnson & Johnson.

Enrollment
37th of 54
39 · median 115
Started
2017
with 2 others
Phase 1
21 of 62
none open now
Registered
58th of 62
by date

Among the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson, this one is the 37th largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2017, is one of 21 in phase 1, and was the 58th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 62 studies in Diabetes Mellitus, Type 2 by Johnson & Johnson as a file.
02

Study summary

The purpose of this Phase 1b study is to assess the safety and tolerability of JNJ-64565111 in adult men and women (of non-child bearing potential) with Type 2 Diabetes Mellitus.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus (T2DM) at least 3 months prior to Screening
  • (HbA1c) greater than or equal to (>=) 7.0 percent (%) and lesser than or equal to (\<=)9.5% at Screening
  • On a stable treatment regimen for at least 3 months prior to Screening of (1) diet and exercise, and/or (2) metformin monotherapy (at a dose of at least 1,000 milligram (mg) per day)
  • (BMI) ranging from 25 to 40 kilogram per square meter (kg/m\^2) (inclusive), weighing between 75 and 130 kg (inclusive)
  • A woman must have a negative highly sensitive serum beta-human chorionic gonadotropin (beta- hCG) at Screening and Day -2
  • Blood pressure (measured after the participant is sitting/ resting quietly for 5 minutes) between 90 and 140 millimeter of mercury (mmHg) systolic, inclusive, and between 60 and 100 mmHg diastolic, inclusive at Screening (sitting) and Day -2 (supine). If the average of the first triplicate blood pressure assessment is out of range, up to 2 repeated triplicate assessments are permitted

Exclusion criteria

Exclusion Criteria:

  • History or current diagnosis of acute or chronic pancreatitis
  • Familial or personal history of multiple endocrine neoplasia type 2,familial/non-familial medullary thyroid carcinoma
  • Donated blood or blood products or lost a significant amount of blood (>500 milliliter [mL]) within 3 months before the first administration of study drug
  • History of surface antigen (HBsAg) or antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HBsAg or anti-HCV at Screening
  • History of (HIV) antibody positive, or tests positive for HIV at Screening
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Cohort 1 to 4: JNJ-64565111 or Placebo

    Participants in cohort 1 to 4 in a ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22. Cohort 1, 2 and 3 will be dosed in parallel. Dosing for subsequent cohort 4 will be escalated based on review by the Sponsor and Principal Investigator of blinded safety, tolerability, pharmacokinetic, and (all available) pharmacodynamic data collected up to Day 29, but will not exceed from well-tolerated dose.

    Drug: JNJ-64565111 · Drug: Placebo

  • Experimental
    Cohort 5: JNJ-64565111 (Repeat or Lower Dose) or Placebo

    Participants in ratio of 4:1 will receive a dose of JNJ-64565111 or placebo subcutaneously on Days 1, 8, 15 and 22, and may be modified. The dose can be repeated or lower than a dose previously assessed as well tolerated.

    Drug: JNJ-64565111 · Drug: Placebo

Interventions

  • Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.

    Also known as: Oxyntomodulin

  • DrugPlacebo

    Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.

    Time frame: Up to Day 72

Secondary outcomes

  1. Maximum Observed Serum Concentration (Cmax)

    Maximum observed serum concentration (Cmax) of JNJ-64565111 will be assessed.

    Time frame: First Dose: Predose (Day 1), and at 8, 24, 48, 72 and 120 hours post-dose (PD); Fourth Dose: predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD.

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)

    Actual sampling time to reach maximum observed serum concentration (Tmax) of JNJ-64565111 will be assessed.

    Time frame: First Dose: Predose (Day 1), and at 8, 24, 48, 72 and 120 hours post-dose (PD); Fourth Dose: predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD

  3. Area Under Concentration-Time Curve From Time Zero to the Last Quantifiable Time (AUC [0-last])

    The AUC (0-last) of JNJ-64565111 is the area under the serum concentration-time curve from time zero to last quantifiable time.

    Time frame: First Dose: Predose (Day 1), and at 8, 24, 48, 72 and 120 hours post-dose (PD)

  4. Average Concentration Over the Dosing Interval Tau (T) at Steady State (Caverage,ss)

    Average concentration over the dosing interval tau at steady state of JNJ-64565111 (defined as area under the serum concentration time curve observed during a dosing interval (tau) at steady state) will be calculated as AUC(0- T)/T.

    Time frame: Fourth Dose: Predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD

  5. Minimum Observed Serum Concentration (Cmin)

    Minimum observed serum concentration (Cmin) of JNJ-64565111 will be assessed.

    Time frame: Fourth Dose: Predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD

  6. Accumulation Ratio

    Accumulation ratio of JNJ-64565111, calculated as AUC(0-T), Day 22 / AUC(0-T), Day 1 will be assessed after last dose.

    Time frame: First Dose: Predose (Day 1), and at 8, 24, 48, 72 and 120 hours post-dose (PD); Fourth Dose: predose (Day 22), and at 72, 96, 144, 168 hours PD

  7. Area Under Curve over the dosing interval AUC (0-T)

    The AUC (0-T) of JNJ-64565111 is the measure of the serum drug concentration from time zero to end of dosing interval. It is used to characterize drug absorption.

    Time frame: Fourth Dose: Predose (Day 22), and at 72, 96, 144, 168 hours PD

  8. Apparent Terminal Elimination Half-life (t1/2term)

    Apparent terminal elimination half-life of JNJ-64565111, calculated as 0.693/apparent terminal elimination rate constant (Lambda\[z\]).

    Time frame: Fourth Dose: Predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD

  9. Apparent Clearance (CL/F)

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after subcutaneous (SC) dose (apparent SC clearance) is influenced by the fraction of the dose absorbed. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. CL/F will be calculated as CL/F = Dose/AUC \[0-infinity\].

    Time frame: Fourth Dose: Predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD

  10. Apparent Volume of Distribution (V/F)

    Apparent volume of distribution of JNJ-64565111 is based on the terminal phase following subcutaneous administration calculated as Vd/F = Dose/ apparent terminal elimination rate constant (Lambda\[z\])\*AUC \[0-infinity\].

    Time frame: Fourth Dose: Predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD

  11. Terminal Rate Constant (Kel)

    Terminal rate constant of JNJ-64565111 is defined as the fraction of drug that is eliminated per unit of time (fraction/hour).

    Time frame: Fourth Dose: Predose (Day 22), and at 72, 96, 144, 168, 312, 480, 720, and 1200 hours PD

  12. Number of Participants With Anti-JNJ-64565111 Antibodies as Measure of Immunogenicity

    Immunogenicity will be measured by evaluating serum samples collected from participants. Serum samples will be screened for antibodies binding to JNJ-64565111. The titer of confirmed positive samples will be reported.

    Time frame: First Dose: Predose (Day 1); Second Dose: predose (Day 8) Third Dose: predose (Day 15); Fourth Dose: predose (Day 22), 144, 480, 720, and 1200 hours post-dose.

  13. Change From Baseline in Body Weight

    Body weight will be measured using a calibrated scale at each time a participant is weighed. Calibration must be documented in a calibration log.

    Time frame: Baseline, Days 8, 15, 22, 28, 29, 35, 42, 52, and 72

  14. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change from baseline in fasting plasma glucose (FPG) will be assessed.

    Time frame: Baseline, Days 8, 15, 22, 28, 29, 35, 42, 52, and 72

  15. Change From Baseline in Hemoglobin A1c (HbA1c)

    Change from baseline in HbA1c will be assessed.

    Time frame: Baseline, Days 8, 15, 22, 28, 29, 35, 42, 52, and 72

  16. Change From Baseline in Fasting Lipids

    Fasting plasma lipids were measured to determine the total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol, very low-density lipoprotein cholesterol (VLDL-C), triglycerides and free fatty acids to understand the potential impact of study drug on cardiovascular disease risk.

    Time frame: Baseline, Days 8, 15, 22, 28, 29, 35, 42, 52, and 72

  17. Change From Baseline for 24-hour Mean Plasma Glucose

    Mean plasma glucose defined as the total and/or incremental (that is, baseline-subtracted) area under the concentration (AUC) time curve over 0 to 24 hours, divided by 24.

    Time frame: Baseline, Day 26

  18. Change From Baseline in C-peptide Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)

    MMTT-Stimulated 6-Hour C-peptide AUC is the mean area under the C-peptide level-time curve over the 6-hour period divided by the duration after a mixed-meal tolerance test.

    Time frame: Baseline, Day 26

  19. Change From Baseline in Total and/or Incremental Plasma Glucose Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)

    MMTT-Stimulated 6-Hour total and/or incremental plasma glucose AUC is the mean area under the total and/or incremental plasma glucose level-time curve over the 6-hour period divided by the duration after a mixed-meal tolerance test.

    Time frame: Baseline, Day 26

  20. Change From Baseline in Insulin Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)

    MMTT-Stimulated 6-Hour Insulin AUC is the mean area under the insulin level-time curve over the 6-hour period divided by the duration after a mixed-meal tolerance test.

    Time frame: Baseline, Day 26

  21. Change From Baseline in Glucagon Area Under the Curve (AUC) Calculated From a 6-Hour Mixed Meal Tolerance Test (MMTT)

    MMTT-Stimulated 6-Hour Glucagon AUC is the mean area under the glucagon level-time curve over the 6-hour period divided by the duration after a mixed-meal tolerance test.

    Time frame: Baseline, Day 26

  22. Change From Baseline in 24-hour Blood Pressure

    Blood Pressure will be assessed by 24-hour ambulatory blood pressure and heart rate monitoring (ABPM) device by periodic measurements performed at 1 hour intervals for the first 14 hours, then at 2-hour intervals for the remaining 10 hours (that is, 19 measurements in total).

    Time frame: Baseline and Day 28

  23. Change From Baseline in 24-hour Heart Rate

    Heart rate measurements will be assessed with a completely automated (ambulatory blood pressure and heart rate monitoring) device.

    Time frame: Baseline and Day 28

  24. Change From Baseline in Body Mass Index (BMI)

    Body Mass Index (BMI) is calculated by dividing the body weight (in kilogram) by the square of height (in meters).

    Time frame: Baseline, Days 8, 15, 22, 28, 29, 35, 42, 52, and 72

  25. Change From Baseline Insulin Secretion as Assessed by the Insulinogenic Index

    Insulin secretion will be assessed by the insulinogenic index (Insulin 30-Insulin 0)/(Glucose 30-Glucose 0), by measuring the ratio of insulin to glucose. The insulinogenic index is frequently used as a measure of beta cell function.

    Time frame: Baseline, Day 26

  26. Change from Baseline in Insulin Secretion as Assessed by Homeostasis Model Assessment of Beta Cell Function (HOMA-%B)

    HOMA is used to quantify insulin resistance and beta-cell function from basal (fasting) glucose and insulin (or C-peptide) concentrations. HOMA-B will be calculated by 20\*I/(G-3.5) where I is fasting plasma insulin (micro units/per milliliter \[uU/mL\]) and G is fasting plasma glucose (millimoles per liter \[mmol/L\]).

    Time frame: Baseline, Day 26

  27. Change From Baseline in Insulin Sensitivity as Assessed by Matsuda Index

    The Matsuda index represents a composite of both hepatic and peripheral tissue sensitivity to insulin. Insulin sensitivity by Matsuda Index will be calculated by (10,000/square root of \[fasting glucose \* fasting insulin\] \* \[mean glucose \* mean insulin during oral glucose tolerance test \[OGTT\]).

    Time frame: Baseline, Day 26

  28. Change From Baseline in Insulin Sensitivity as Assessed by Homeostasis Model Assessment for Insulin Sensitivity (HOMA-%S)

    Insulin sensitivity will be assessed by Homeostasis Model Assessment (HOMA-%S) where HOMA-%S is 100/HOMA-Insulin Resistance \[IR\]. The HOMA-IR is the product of the blood Glucose and Insulin levels, divided by a constant. HOMA-IR is expressed as the following: HOMA-IR = fasting serum insulin (uU/mL) \* fasting plasma glucose (mmol/L) / 22.5.

    Time frame: Baseline, Day 26

07

Study locations

2 sites
  • ProSciento, Inc.
    Chula Vista, California 91911, United States
  • Advanced Pharma CR, LLC
    Miami, Florida 33147, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Feb 2018, 6 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 6 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2017
First posted
Aug 1, 2017
StartActual
Aug 1, 2017
Primary completionActual
Feb 19, 2018
CompletionActual
Feb 19, 2018
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03235219
Responsible party
Sponsor
First posted
Aug 1, 2017
Start date
Aug 1, 2017
Primary completion
Feb 19, 2018
Completion
Feb 19, 2018
Last update
Apr 27, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion